CoChat

ORIGINAL ARTICLE: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2‐year follow‐up study

Berberoglu, Zehra, Yazici, Ayse C., Demirag, Nilgun G. · 2010 · Clinical Endocrinology
Cited by 44

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Summary: Objective To evaluate the effect of rosiglitazone on bone metabolism and bone density. Design An open‐label, randomized, controlled trial of 24‐month duration. Patients and measurements Obese, postmenopausal women with newly diagnosed diabetes were studied. Before and after the intervention, metabolic bone markers and bone density were assessed. Results Twenty‐six patients received rosiglitazone (4 mg/day), and 23 remained on diet alone. Serum bone‐specific alkaline phosphatase and osteocalcin levels decreased by 17% (P < 0·001 vs control group) and 26% (P < 0·01 vs control group), respectively, in the rosiglitazone group. There were no significant changes in the deoxypyridinoline levels between the two groups. Annual bone loss at the trochanter and at the lumbar spine associated with each year of rosiglitazone use was 2·56% (P = 0·01 vs control group) and 2·18% (P < 0·01 vs control group), respectively. Femoral neck and total hip bone density declined significantly in both groups (P < 0·01, and P = 0·01, respectively) but was not significantly different between the two groups. Conclusions Rosiglitazone treatment adversely affects bone formation over a 2‐year period. It increases bone loss at the lumbar spine and trochanter in postmenopausal, type 2 diabetic women. However, bone loss at the total hip did not differ with use of this agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2010.03784.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 44

Metadata

Authors
Berberoglu, Z., Yazici, A. C., & Demirag, N. G.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2010-08-17
Volume
73
Issue
3
Pages
305-312
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W1544352279
Cited by
44
References
5
FWCI
5.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ORIGINAL ARTICLE: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2‐year follow‐up study. https://app.cochat.ai/papers/10.1111/j.1365-2265.2010.03784.x
The paper
Berberoglu, Z., Yazici, A. C., & Demirag, N. G. (2010). ORIGINAL ARTICLE: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2‐year follow‐up study. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2010.03784.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.